Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 3 Saturday Sunday Monday SATURDAY, DECEMBER 7 TH 5:30pm - 7:00pm Pacific Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 2383 A Patient Perspective on Actionable Steps to Address Disparities in Healthcare Among US Patients with Multiple Myeloma Gilbert O Gentry E Outcomes Research: Plasma Cell Disorders: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 1514 Time to Response and Overall Survival in Patients with mIDH1 Relapsed/ Refractory Acute Myeloid Leukemia Treated with Olutasidenib Wang ES Donnellan WB Acute Myeloid Leukemias: Commercially Available Therapies: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 1982 Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM) Vesole DH Schade H, Matous JV Multiple Myeloma: Pharmacologic Therapies: Poster I 5:30 - 7:30pm San Diego Convention Center, Halls G-H Poster 2069 BMS-986393, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 13 Prior Regimens: Updated Phase 1 Safety and Efficacy Results Bal S Gregory T Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I SUNDAY, DECEMBER 8 TH 9:30am - 11:00am Pacific Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:30 - 11:00am 9:30am Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8–9 Oral 469 Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes Salles G Sharman JP, Burke J Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma 9:30 - 11:00am 9:30am Manchester Grand Hyatt, Harbor Ballroom DEFG Oral 475 Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator- Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study Cortes JE Andorsky D Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice 9:30 - 11:00am 9:30am Marriott Marquis Pacific Ballroom Salons 24-26 Oral 523 Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above Muhsen I Majhail N, Battiwalla M, Malik SA, Mathews J, Shaughnessy P, Mountjoy L Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma